WAVE LIFE SCIENCES LTD. Restructuring Charges
WAVE LIFE SCIENCES LTD. (WVE) reported Restructuring Charges of $3.40 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2020-11-09
- WAVE LIFE SCIENCES LTD. restructuring charges for the quarter ending 2020-09-30 was $0.00.
- WAVE LIFE SCIENCES LTD. restructuring charges for the quarter ending 2020-06-30 was $15.00K.
- WAVE LIFE SCIENCES LTD. restructuring charges for the quarter ending 2020-03-31 was $3.38M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $15.00K derived: sum of 2 quarters · filed 2020-11-09 | $3.40M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $3.40M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $3.38M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |